vs

Side-by-side financial comparison of COLONY BANKCORP INC (CBAN) and Editas Medicine, Inc. (EDIT). Click either name above to swap in a different company.

COLONY BANKCORP INC is the larger business by last-quarter revenue ($39.9M vs $24.7M, roughly 1.6× Editas Medicine, Inc.). COLONY BANKCORP INC runs the higher net margin — 20.6% vs -22.7%, a 43.3% gap on every dollar of revenue. Over the past eight quarters, Editas Medicine, Inc.'s revenue compounded faster (366.9% CAGR vs 19.6%).

Colony Bankcorp Inc is a US-based bank holding company that operates Colony Bank. It provides a full suite of personal and commercial banking services including deposit accounts, consumer and business loans, mortgage services, and wealth management solutions, primarily serving retail customers and small-to-medium enterprises across the state of Georgia.

Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

CBAN vs EDIT — Head-to-Head

Bigger by revenue
CBAN
CBAN
1.6× larger
CBAN
$39.9M
$24.7M
EDIT
Higher net margin
CBAN
CBAN
43.3% more per $
CBAN
20.6%
-22.7%
EDIT
Faster 2-yr revenue CAGR
EDIT
EDIT
Annualised
EDIT
366.9%
19.6%
CBAN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CBAN
CBAN
EDIT
EDIT
Revenue
$39.9M
$24.7M
Net Profit
$8.2M
$-5.6M
Gross Margin
Operating Margin
-31.3%
Net Margin
20.6%
-22.7%
Revenue YoY
-19.2%
Net Profit YoY
24.1%
87.6%
EPS (diluted)
$0.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CBAN
CBAN
EDIT
EDIT
Q1 26
$39.9M
Q4 25
$36.9M
$24.7M
Q3 25
$32.8M
$7.5M
Q2 25
$32.5M
$3.6M
Q1 25
$30.0M
$4.7M
Q4 24
$30.8M
$30.6M
Q3 24
$28.6M
$61.0K
Q2 24
$27.9M
$513.0K
Net Profit
CBAN
CBAN
EDIT
EDIT
Q1 26
$8.2M
Q4 25
$-5.6M
Q3 25
$5.8M
$-25.1M
Q2 25
$8.0M
$-53.2M
Q1 25
$6.6M
$-76.1M
Q4 24
$-45.4M
Q3 24
$5.6M
$-62.1M
Q2 24
$5.5M
$-67.6M
Operating Margin
CBAN
CBAN
EDIT
EDIT
Q1 26
Q4 25
25.9%
-31.3%
Q3 25
22.2%
-325.4%
Q2 25
30.9%
-1440.6%
Q1 25
27.6%
-1635.1%
Q4 24
28.8%
-152.2%
Q3 24
24.6%
-107649.2%
Q2 24
24.8%
-14016.2%
Net Margin
CBAN
CBAN
EDIT
EDIT
Q1 26
20.6%
Q4 25
-22.7%
Q3 25
17.7%
-333.0%
Q2 25
24.6%
-1487.8%
Q1 25
22.0%
-1633.5%
Q4 24
-148.3%
Q3 24
19.7%
-101870.5%
Q2 24
19.6%
-13178.8%
EPS (diluted)
CBAN
CBAN
EDIT
EDIT
Q1 26
Q4 25
$0.42
$0.03
Q3 25
$0.33
$-0.28
Q2 25
$0.46
$-0.63
Q1 25
$0.38
$-0.92
Q4 24
$0.43
$-0.55
Q3 24
$0.32
$-0.75
Q2 24
$0.31
$-0.82

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CBAN
CBAN
EDIT
EDIT
Cash + ST InvestmentsLiquidity on hand
$295.8M
$146.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$380.4M
$27.3M
Total Assets
$3.7B
$186.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CBAN
CBAN
EDIT
EDIT
Q1 26
$295.8M
Q4 25
$146.6M
Q3 25
$165.6M
Q2 25
$178.5M
Q1 25
$221.0M
Q4 24
$269.9M
Q3 24
$265.1M
Q2 24
$279.1M
Total Debt
CBAN
CBAN
EDIT
EDIT
Q1 26
Q4 25
$258.1M
Q3 25
Q2 25
Q1 25
Q4 24
$248.0M
$57.4M
Q3 24
Q2 24
Stockholders' Equity
CBAN
CBAN
EDIT
EDIT
Q1 26
$380.4M
Q4 25
$375.9M
$27.3M
Q3 25
$302.3M
$13.5M
Q2 25
$293.9M
$19.2M
Q1 25
$286.9M
$62.4M
Q4 24
$278.7M
$134.3M
Q3 24
$276.1M
$175.6M
Q2 24
$264.7M
$232.0M
Total Assets
CBAN
CBAN
EDIT
EDIT
Q1 26
$3.7B
Q4 25
$3.7B
$186.5M
Q3 25
$3.2B
$201.8M
Q2 25
$3.1B
$210.6M
Q1 25
$3.2B
$263.7M
Q4 24
$3.1B
$341.6M
Q3 24
$3.1B
$327.6M
Q2 24
$3.0B
$384.8M
Debt / Equity
CBAN
CBAN
EDIT
EDIT
Q1 26
Q4 25
0.69×
Q3 25
Q2 25
Q1 25
Q4 24
0.89×
0.43×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CBAN
CBAN
EDIT
EDIT
Operating Cash FlowLast quarter
$-36.4M
Free Cash FlowOCF − Capex
$-36.4M
FCF MarginFCF / Revenue
-147.3%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CBAN
CBAN
EDIT
EDIT
Q1 26
Q4 25
$-5.5M
$-36.4M
Q3 25
$14.4M
$-30.8M
Q2 25
$15.8M
$-50.2M
Q1 25
$17.9M
$-47.8M
Q4 24
$23.4M
$-50.8M
Q3 24
$20.5M
$-52.6M
Q2 24
$1.1M
$-57.1M
Free Cash Flow
CBAN
CBAN
EDIT
EDIT
Q1 26
Q4 25
$-6.9M
$-36.4M
Q3 25
$14.1M
$-31.3M
Q2 25
$15.8M
Q1 25
$17.6M
$-47.9M
Q4 24
$22.3M
$-51.3M
Q3 24
$20.2M
$-55.5M
Q2 24
$990.0K
$-60.6M
FCF Margin
CBAN
CBAN
EDIT
EDIT
Q1 26
Q4 25
-18.7%
-147.3%
Q3 25
42.9%
-414.6%
Q2 25
48.5%
Q1 25
58.7%
-1028.6%
Q4 24
72.5%
-167.6%
Q3 24
70.6%
-90998.4%
Q2 24
3.5%
-11804.3%
Capex Intensity
CBAN
CBAN
EDIT
EDIT
Q1 26
Q4 25
3.7%
0.2%
Q3 25
1.1%
5.7%
Q2 25
0.3%
0.0%
Q1 25
1.2%
2.4%
Q4 24
3.5%
1.8%
Q3 24
1.0%
4788.5%
Q2 24
0.5%
681.1%
Cash Conversion
CBAN
CBAN
EDIT
EDIT
Q1 26
Q4 25
Q3 25
2.48×
Q2 25
1.99×
Q1 25
2.71×
Q4 24
Q3 24
3.64×
Q2 24
0.20×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CBAN
CBAN

Net Interest Income$29.2M73%
Noninterest Income$10.7M27%

EDIT
EDIT

Segment breakdown not available.

Related Comparisons